Results 1 to 10 of about 517,948 (338)

The cytokine receptor CRLF3 is a human neuroprotective EV-3 (Epo) receptor [PDF]

Frontiers in Molecular Neuroscience, 2023
The evolutionary conserved orphan cytokine receptor-like factor 3 (CRLF3) has been implicated in human disease, vertebrate hematopoiesis and insect neuroprotection.
Debbra Y. Knorr, Ignacio Rodriguez Polo, Ignacio Rodriguez Polo, Ignacio Rodriguez Polo, Ignacio Rodriguez Polo, Hanna S. Pies, Nicola Schwedhelm-Domeyer, Stephanie Pauls, Rüdiger Behr, Rüdiger Behr, Ralf Heinrich   +10 more
doaj   +2 more sources

Cytokine Receptor-Like Factor 3 (CRLF3) Contributes to Early Zebrafish Hematopoiesis [PDF]

Frontiers in Immunology, 2022
Cytokine receptor-like factor 3 (CRLF3) is an ancient protein conserved across metazoans that contains an archetypal cytokine receptor homology domain (CHD).
Tarannum Taznin, Kaushalya Perera, Yann Gibert, Alister C. Ward, Alister C. Ward, Clifford Liongue, Clifford Liongue   +6 more
doaj   +2 more sources

In Situ Identification of Both IL-4 and IL-10 Cytokine–Receptor Interactions during Tissue Regeneration [PDF]

Cells, 2023
Cytokines secreted by individual immune cells regulate tissue regeneration and allow communication between various cell types. Cytokines bind to cognate receptors and trigger the healing process.
Krisztina Nikovics, Anne-Laure Favier, Mathilde Rocher, Céline Mayinga, Johanna Gomez, Frédérique Dufour-Gaume, Diane Riccobono   +6 more
doaj   +2 more sources

Cytokine-Leukotriene Receptor Interactions [PDF]

The Scientific World Journal, 2007
Biochemical and pharmacological studies have identified the structure of leukotrienes, the pathways that lead to their synthesis, and the signaling events they trigger when they interact with their cognate receptors.
Marek Rola-Pleszczynski, Jana Stankova
doaj   +4 more sources

Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

Scientific Reports, 2021
Type I Interferon (IFN) was the very first drug approved for the treatment of Multiple Sclerosis (MS), and is still frequently used as a first line therapy. However, systemic IFN also causes considerable side effects, affecting therapy adherence and dose
Anje Cauwels, Sandra Van Lint, Elke Rogge, Annick Verhee, Bram Van Den Eeckhout, Shengru Pang, Marco Prinz, Niko Kley, Gilles Uzé, Jan Tavernier   +9 more
doaj   +1 more source

Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers

eLife, 2023
Dimerization of the thrombopoietin receptor (TpoR) is necessary for receptor activation and downstream signaling through activated Janus kinase 2. We have shown previously that different orientations of the transmembrane (TM) helices within a receptor ...
Jean-Philippe Defour, Emilie Leroy, Sharmila Dass, Thomas Balligand, Gabriel Levy, Ian C Brett, Nicolas Papadopoulos, Céline Mouton, Lidvine Genet, Christian Pecquet, Judith Staerk, Steven O Smith, Stefan N Constantinescu   +12 more
doaj   +1 more source

Identification of cytokine-induced cell communications by pan-cancer meta-analysis [PDF]

PeerJ, 2023
Cancer immune responses are complex cellular processes in which cytokine–receptor interactions play central roles in cancer development and response to therapy; dysregulated cytokine–receptor communication may lead to pathological processes, including ...
Yining Liu, Min Zhao, Hong Qu
doaj   +2 more sources

Interleukin-2 signalling is modulated by a labile disulfide bond in the CD132 chain of its receptor [PDF]

Open Biology, 2012
Certain disulfide bonds present in leucocyte membrane proteins are labile and can be reduced in inflammation. This can cause structural changes that result in downstream functional effects, for example, in integrin activation.
Clive Metcalfe, Peter Cresswell, A. Neil Barclay   +2 more
doaj   +1 more source

Discovery of a novel potentially transforming somatic mutation in CSF2RB gene in breast cancer

Cancer Medicine, 2021
The colony stimulating factor 2 receptor subunit beta (CSF2RB) is the common signaling subunit of the cytokine receptors for IL‐3, IL‐5, and GM‐CSF. Several studies have shown that spontaneous and random mutants of CSF2RB can lead to ligand independence ...
Mamoon Rashid, Rizwan Ali, Bader Almuzzaini, Hao Song, Alshaimaa AlHallaj, Al Abdulrahman Abdulkarim, Omar Mohamed Baz, Hajar Al Zahrani, Muhammed Mustafa Sabeena, Wardah Alharbi, Mohamed Hussein, Mohamed Boudjelal   +11 more
doaj   +1 more source

Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies

EMBO Molecular Medicine, 2020
Systemic toxicities have severely limited the clinical application of tumor necrosis factor (TNF) as an anticancer agent. Activity‐on‐Target cytokines (AcTakines) are a novel class of immunocytokines with improved therapeutic index.
Leander Huyghe, Alexander Van Parys, Anje Cauwels, Sandra Van Lint, Stijn De Munter, Jennyfer Bultinck, Lennart Zabeau, Jeroen Hostens, An Goethals, Nele Vanderroost, Annick Verhee, Gilles Uzé, Niko Kley, Frank Peelman, Bart Vandekerckhove, Peter Brouckaert, Jan Tavernier   +16 more
doaj   +1 more source